Stopping the progression of SMA in your child is essential
ZOLGENSMA is proven to work with just one dose
Louis has 2 copies of SMN2 gene
Treated at ~2½ months old
After receiving treatment with ZOLGENSMA,
Louis received another SMA treatment.
ZOLGENSMA® (onasemnogene abeparvovec-xioi) has been studied in children with spinal muscular atrophy (SMA), including those with no known spinal muscular atrophy symptoms, as well as those already showing symptoms at the time of treatment.
SMA can take away vital motor neurons, which may lead to a loss of muscle function. Once these neurons are lost, they can’t be regained. The good news is that early detection and diagnosis are widely available and early treatment with ZOLGENSMA can stop the progression of SMA. It’s important to remember that the sooner a child is treated, the more their muscle function can be preserved. Many parents may get their child’s SMA diagnosis before symptoms appear (also known as presymptomatic); others may learn of their child’s diagnosis after their child starts having symptoms (also known as symptomatic).